United Therapeutics Corporation (UTHR) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Silver Spring, MD, United States. Der aktuelle CEO ist Martine A. Rothblatt.
UTHR hat IPO-Datum 1999-06-17, 1,305 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $25.36B.
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with chronic and life-threatening diseases, particularly pulmonary hypertension and related conditions. The company's commercial portfolio includes Remodulin, Tyvaso, Orenitram, and Adcirca for treating pulmonary arterial hypertension, as well as Unituxin for high-risk neuroblastoma. United Therapeutics maintains an active pipeline of innovative treatments including gene therapies, advanced drug delivery systems, and next-generation formulations, supported by strategic partnerships with leading medical device and pharmaceutical companies. Headquartered in Silver Spring, Maryland, the company operates globally to address significant unmet medical needs in pulmonary hypertension and oncology.
